315 related articles for article (PubMed ID: 29884444)
1. Risk of Melanoma With Phosphodiesterase Type 5 Inhibitor Use Among Patients With Erectile Dysfunction, Pulmonary Hypertension, and Lower Urinary Tract Symptoms.
Shkolyar E; Li S; Tang J; Eisenberg ML
J Sex Med; 2018 Jul; 15(7):982-989. PubMed ID: 29884444
[TBL] [Abstract][Full Text] [Related]
2. Erectile Dysfunction Medications and Skin Cancer: An Analysis in US Veterans.
Christie A; Vera PL; Higgins M; Kumar S; Lane M; Preston D
Urology; 2019 Apr; 126():116-120. PubMed ID: 30735744
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular Outcome Risks in Patients With Erectile Dysfunction Co-Prescribed a Phosphodiesterase Type 5 Inhibitor (PDE5i) and a Nitrate: A Retrospective Observational Study Using Electronic Health Record Data in the United States.
Nunes AP; Seeger JD; Stewart A; Gupta A; McGraw T
J Sex Med; 2021 Sep; 18(9):1511-1523. PubMed ID: 34389264
[TBL] [Abstract][Full Text] [Related]
4. Combination Therapy with Alpha-blocker and Phosphodiesterase-5 Inhibitor for Improving Lower Urinary Tract Symptoms and Erectile Dysfunction in Comparison with Monotherapy: A Systematic Review and Meta-analysis.
Kallidonis P; Adamou C; Kotsiris D; Ntasiotis P; Verze P; Athanasopoulos A;
Eur Urol Focus; 2020 May; 6(3):537-558. PubMed ID: 31133414
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer.
Lian Y; Yin H; Pollak MN; Carrier S; Platt RW; Suissa S; Azoulay L
Eur Urol; 2016 Nov; 70(5):808-815. PubMed ID: 27178449
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients With Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial.
Kim SW; Park NC; Lee SW; Yang DY; Park JK; Moon DG; Yang SK; Lee SW; Moon KH; Ahn TY; Kim SW; Park K; Min KS; Ryu JK; Son H; Jung J; Hyun JS
J Sex Med; 2017 Aug; 14(8):1018-1027. PubMed ID: 28760246
[TBL] [Abstract][Full Text] [Related]
7. Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction.
Yafi FA; Sharlip ID; Becher EF
Sex Med Rev; 2018 Apr; 6(2):242-252. PubMed ID: 28923561
[TBL] [Abstract][Full Text] [Related]
8. Sexual Rehabilitation After Nerve-Sparing Radical Prostatectomy: Free-of-Charge Phosphodiesterase Type 5 Inhibitor Administration Improves Compliance to Treatment.
Siena G; Mari A; Canale A; Mondaini N; Chindemi A; Greco I; Saleh O; Serni S; Nicita G; Minervini A; Carini M
J Sex Med; 2018 Feb; 15(2):120-123. PubMed ID: 29425663
[TBL] [Abstract][Full Text] [Related]
9. Erectile Dysfunction Medications and Treatment for Cardiometabolic Risk Factors: A Pharmacoepidemiologic Study.
Skeldon SC; Cheng L; Morgan SG; Detsky AS; Goldenberg SL; Law MR
J Sex Med; 2017 Dec; 14(12):1597-1605. PubMed ID: 29198514
[TBL] [Abstract][Full Text] [Related]
10. [PDE5: A new therapeutic target for lower urinary tract symptoms/ benign prostatic hyperplasia combined with erectile dysfunction].
Xu Z; Jia RP
Zhonghua Nan Ke Xue; 2018 Apr; 24(4):355-359. PubMed ID: 30168958
[TBL] [Abstract][Full Text] [Related]
11. Phosphodiesterase Type 5 Inhibitors in Men With Erectile Dysfunction and the Risk of Alzheimer Disease: A Cohort Study.
Adesuyan M; Jani YH; Alsugeir D; Howard R; Ju C; Wei L; Brauer R
Neurology; 2024 Feb; 102(4):e209131. PubMed ID: 38324745
[TBL] [Abstract][Full Text] [Related]
12. Erectile Dysfunction and Lower Urinary Tract Symptoms.
De Nunzio C; Lombardo R; Tema G; Tubaro A
Curr Urol Rep; 2018 Jun; 19(8):61. PubMed ID: 29858709
[TBL] [Abstract][Full Text] [Related]
13. PDE-5 Inhibitors for BPH-Associated LUTS.
Brousil P; Shabbir M; Zacharakis E; Sahai A
Curr Drug Targets; 2015; 16(11):1180-6. PubMed ID: 26470799
[TBL] [Abstract][Full Text] [Related]
14. An Evaluation of a Clinical Care Pathway for the Management of Men With Nonorganic Erectile Dysfunction.
Jenkins LC; Hall M; Deveci S; Guhring P; Parker M; Nelson CJ; Mulhall JP
J Sex Med; 2019 Oct; 16(10):1541-1546. PubMed ID: 31444103
[TBL] [Abstract][Full Text] [Related]
15. Use of phosphodiesterase 5 inhibitors is not associated with ocular adverse events.
Belladelli F; Li S; Zhang CA; Muncey W; Del Giudice F; Glover F; Seranio N; Basran S; Fallara G; Montorsi F; Salonia A; Eisenberg ML
J Sex Med; 2023 Nov; 20(12):1399-1406. PubMed ID: 37861186
[TBL] [Abstract][Full Text] [Related]
16. The Association Between Insomnia, Insomnia Medications, and Erectile Dysfunction.
Belladelli F; Li S; Zhang CA; Del Giudice F; Basran S; Muncey W; Glover F; Seranio N; Fallara G; Montorsi F; Salonia A; Eisenberg ML
Eur Urol Focus; 2024 Jan; 10(1):139-145. PubMed ID: 37690918
[TBL] [Abstract][Full Text] [Related]
17. Risk of Death in Patients With Coronary Artery Disease Taking Nitrates and Phosphodiesterase-5 Inhibitors.
Trolle Lagerros Y; Grotta A; Freyland S; Grannas D; Andersson DP
J Am Coll Cardiol; 2024 Jan; 83(3):417-426. PubMed ID: 38233015
[TBL] [Abstract][Full Text] [Related]
18. Meta-Analysis of the Association Between Phosphodiesterase Inhibitors (PDE5Is) and Risk of Melanoma.
Loeb S; Ventimiglia E; Salonia A; Folkvaljon Y; Stattin P
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 29117385
[TBL] [Abstract][Full Text] [Related]
19. Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment.
Loeb S; Folkvaljon Y; Robinson D; Schlomm T; Garmo H; Stattin P
Eur Urol; 2016 Nov; 70(5):824-828. PubMed ID: 26743040
[TBL] [Abstract][Full Text] [Related]
20. Study of phosphodiesterase 5 inhibitors and α-adrenoceptor antagonists used alone or in combination for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.
Sun Y; Peng B; Lei GL; Wei Q; Yang L
Minerva Urol Nefrol; 2020 Feb; 72(1):13-21. PubMed ID: 31241273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
